Clemons MJ - Search Results

1

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.

Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B. Van Poznak C, et al. Among authors: clemons mj. J Clin Oncol. 2017 Dec 10;35(35):3978-3986. doi: 10.1200/JCO.2017.75.4614. Epub 2017 Oct 16. J Clin Oncol. 2017. PMID: 29035643

2

Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience.

Enright K, Clemons M, Chow E. Enright K, et al. Support Care Cancer. 2004 Jan;12(1):48-52. doi: 10.1007/s00520-003-0548-3. Epub 2003 Oct 24. Support Care Cancer. 2004. PMID: 14577020

3

Should all breast cancer patients with symptomatic bone metastases be treated with bisphosphonates? The case in support.

Clemons M. Clemons M. Clin Oncol (R Coll Radiol). 2004 Apr;16(2):108-11. doi: 10.1016/j.clon.2004.01.004. Clin Oncol (R Coll Radiol). 2004. PMID: 15074732 No abstract available.

4

Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists.

Verma S, Kerr-Cresswell D, Dranitsaris G, Charbonneau F, Trudeau M, Yogendran G, Cesta AM, Clemons M. Verma S, et al. Support Care Cancer. 2004 Dec;12(12):852-8. doi: 10.1007/s00520-004-0671-9. Epub 2004 Aug 21. Support Care Cancer. 2004. PMID: 15322969

5

Perspectives on the future of bisphosphonate use in breast cancer patients.

Clemons M, Rea D. Clemons M, et al. Semin Oncol. 2004 Oct;31(5 Suppl 10):87-91. doi: 10.1053/j.seminoncol.2004.07.029. Semin Oncol. 2004. PMID: 15490383 Review.

6

Should oral bisphosphonates be standard of care in women with early breast cancer?

Clemons M, Verma S. Clemons M, et al. Breast Cancer Res Treat. 2005 Apr;90(3):315-8. doi: 10.1007/s10549-004-4259-3. Breast Cancer Res Treat. 2005. PMID: 15830146 Review.

7

Systemic treatment of bone metastases from breast cancer: is it all that it's cracked up to be?

Gainford MC, Dranitsaris G, Clemons M. Gainford MC, et al. J Clin Oncol. 2005 Jul 20;23(21):4802-3; author reply 4803. doi: 10.1200/JCO.2005.01.3490. J Clin Oncol. 2005. PMID: 16034064 No abstract available.

8

Can bone markers guide more effective treatment of bone metastases from breast cancer?

Clemons M, Cole DE, Gainford MC. Clemons M, et al. Breast Cancer Res Treat. 2006 May;97(1):81-90. doi: 10.1007/s10549-005-9094-7. Epub 2005 Dec 1. Breast Cancer Res Treat. 2006. PMID: 16319976 Review.

9

Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer.

Clemons M, Dranitsaris G, Cole D, Gainford MC. Clemons M, et al. Oncologist. 2006 Mar;11(3):227-33. doi: 10.1634/theoncologist.11-3-227. Oncologist. 2006. PMID: 16549806 Free article. Review.

10

Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.

Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L. Chia S, et al. J Clin Oncol. 2006 Jun 20;24(18):2773-8. doi: 10.1200/JCO.2005.03.8331. Epub 2006 May 8. J Clin Oncol. 2006. PMID: 16682726 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

375 results

Search Page

Filters